Clinical Trials


Metabolism of Antituberculosis Drugs in HIV-Infected Persons With Tuberculosis

This study has been completed
National Institute of Allergy and Infectious Diseases (NIAID)

Information provided by (Responsible Party)
National Institute of Allergy and Infectious Diseases (NIAID) Identifier

First received: November 2, 1999
Last updated: March 1, 2011
Last Verified: March 2011
History of Changes


The purpose of this study is to determine if a relationship exists between the level of antituberculosis drugs (isoniazid, rifampin, ethambutol, and pyrazinamide) in the blood and the outcome of HIV-positive patients with tuberculosis. This study also evaluates how these drugs are absorbed and metabolized in the body.

Condition Intervention
HIV Infections

Drug : Ethambutol hydrochloride
Drug : Isoniazid
Drug : Pyrazinamide
Drug : Pyridoxine hydrochloride
Drug : Rifampin

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Pharmacokinetics of Antituberculosis Agents in HIV-Infected Persons With Tuberculosis

Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Enrollment: 50
Primary Completion Date: May 2002 (Final data collection date for primary outcome measure)

Detailed Description:

Patients receive up to 8 weeks of two or more anti-tuberculosis drugs, of which at least two are isoniazid, rifampin, pyrazinamide, or ethambutol. Blood specimens are collected at 2, 6, and 10 hours after administration of study medication, once between Days 10 and 14 of a phase of daily treatment and once while on an intermittent dose regimen (twice weekly or three times weekly).



Ages Eligible for Study: 13 Years and older  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No  


Inclusion Criteria
You may be eligible for this study if you:

  • Are HIV-positive and have tuberculosis.
  • Are 13 years of age or older.
  • Have written, informed consent of parent or guardian if you are under 18 years of age.
  • Agree to practice abstinence or use barrier methods of birth control during the study.

  • Exclusion Criteria
    You will not be eligible for this study if you:
  • Have any other disorder or condition which might cause study treatment to be undesirable.
  • Are pregnant.

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00000950


United States, California
Univ of Southern California / LA County USC Med Ctr
Los Angeles, California, United States, 900331079
Harbor UCLA Med Ctr
Torrance, California, United States, 90502
United States, Florida
University of Miami (Pediatric)
Miami, Florida, United States, 33136
United States, Georgia
Emory Univ
Atlanta, Georgia, United States, 30308
United States, Hawaii
Queens Med Ctr
Honolulu, Hawaii, United States, 96816
Univ of Hawaii
Honolulu, Hawaii, United States, 96816
United States, Louisiana
Tulane Univ School of Medicine
New Orleans, Louisiana, United States, 70112
United States, New York
SUNY / Health Sciences Ctr at Brooklyn
Brooklyn, New York, United States, 112032098
Beth Israel Med Ctr
New York, New York, United States, 10003
St Vincent's Hosp / Mem Sloan-Kettering Cancer Ctr
New York, New York, United States, 10021
Mount Sinai Med Ctr
New York, New York, United States, 10029
United States, Ohio
MetroHealth Med Ctr
Cleveland, Ohio, United States, 441091998
United States, Pennsylvania
Univ of Pennsylvania at Philadelphia
Philadelphia, Pennsylvania, United States, 19104

Sponsors and Collaborators

National Institute of Allergy and Infectious Diseases (NIAID)


Study Chair: Keith Chirgwin
Study Chair: David Perlman
More Information

More Information

Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID) Identifier: NCT00000950   History of Changes  
Other Study ID Numbers: ACTG 309  
Study First Received: November 2, 1999  
Last Updated: March 1, 2011  

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):

AIDS-Related Opportunistic Infections
Drug Therapy, Combination
Acquired Immunodeficiency Syndrome
Antitubercular Agents

Additional relevant MeSH terms:
HIV Infections
Antitubercular Agents
Vitamin B 6 processed this data on July 20, 2018
This information is provided by